JPMorgan lowered the firm’s price target on Doximity (DOCS) to $33 from $40 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $42 from $40 at Piper Sandler
- Down Over 30% This Year: Analysts Double Down on These 3 Beaten-Down Stocks
- Doximity upgraded to Buy from Hold at Canaccord
- Doximity: Network Effects, Normalizing Pharma Budgets, and Undemanding Valuation Create an Attractive Buy Opportunity
- Doximity (DOCS) Earnings Call: AI, Buybacks and Growth